Heterogeneous expression of HER2 within the primary tumor and between primary tumor and metastases has now been reported widely in GC (28), while the prognostic value of HER2 and HER2 heterogeneity also generated controversial results in GC (29–32). This evidence concerns the gene ERBB2 and neoplasm.